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ABSTRACT 
THE REARRANGEMENT OF THE IMMUNOGLOBULIN AND T-CELL RECEPTOR GENES 
IN CHRONIC MYELOGENOUS LEUKEMIA 
Tarik Mustafa Ramahi 
1987 
Although the initial oncogenic events in chronic myelogenous 
leukemia (CML) take place in a pluripotent hematopoietic stem 
cell, with leukemic markers subsequently identifiable in granulo¬ 
cytic, megakaryocytic, erythrocytic, monocytic, and B lymphocytic 
lines, it has been extremely difficult to identify involvement of 
T lymphocytes. In this study T-cell receptor beta chain (TCRB) 
cDNA and immunoglobulin mu constant region (Cmu) cDNA were used 
to probe for TCRB gene and Ig heavy chain gene rearrangements in 
33 patients in the chronic phase of CML, 4 patients in myeloid 
blast crisis, and 4 patients in lymphoid blast crisis. The goals 
of the study were: (i) To look for TCRB gene rearrangements in 
CML blast crisis in an attempt to identify T-cell blast crisis on 
the basis of T-cell surface antigens and rearrangement of the 
TCRB genes, (ii) To see if impending lymphoid blast crisis can be 
identified during the chronic phase of CML on the basis of clonal 
Ig and/or TCR gene rearrangements. (iii) To look for clinical- 
molecular correlations in subgroups of CML patients in lymphoid 
blast crisis. None of the patients in the chronic phase or myel¬ 
oid blast crisis had detectable clonal rearrangements with either 
probe. One of the patients in lymphoid blast crisis demonstrated 
a clonal rearrangement of the TCRB genes in leukemic blasts, T- 
cell phenotype by surface marker analysis, and involvement of the 
breakpoint cluster region (bcr) on chromosome 22. It is concluded 
that this patient represents the second documented case of bona- 
fide T-cell lymphoid blast crisis. A second patient in lymphoid 
blast crisis demonstrated rearrangements of both Ig heavy chain 
and TCRB genes, in addition to involvement of the bcr of chromo¬ 
some 22, in leukemic blasts. This patient's cells lacked B- and 
T-cell surface markers. The presence of dual rearrangements in 
this patient's leukemic DNA reinforced the diagnosis of a blastic 
transformation involving an immature lymphoid progenitor. The two 
other patients in lymphoid blast crisis did not demonstrate 
rearrangements of either Ig heavy chain or TCRB genes. These 
results clearly establish the involvement of the T-cell line in 
the neoplastic proliferation of CML and demonstrate the existence 
of T-cell lymphoid blast crisis. They also indicate that assays 
for Ig and TCR gene rearrangements, as presently performed, 
cannot detect the occurrence of blastic transformation prior to 
onset of clinical manifestations of blast crisis. 
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INTRODUCTION 
I. Chronic Myelogenous Leukemia, a Clonal Myeloproliferative 
Disease. 
Chronic myelogenous leukemia (CML) is a clonal myeloprolifer¬ 
ative disorder arising from a neoplastic transformation of a 
hematopoietic pluripotent stem cell [1-3]. Clinically it is 
characterized by excessive proliferation and accumulation of 
myeloid cells. Two lines of evidence support the theory that CML 
is a clonal disease arising in a stem cell: the presence of the 
Philadelphia (Ph') chromosome and the presence of monoclonal 
patterns of glucose-6-phosphate dehydrogenase (G6PD) isoenzymes 
in hematopoietic cells of diverse lineage (Figure 1). 
The Ph' chromosome (q22~) is an abnormal chromosome 22 
usually produced by a reciprocal translocation of the long arm of 
chromosome 9 to the long arm of chromosome 22 [4-9]. This 
characteristic cytogenetic abnormality, present in 90 to 95% of 
cases of typical CML, has been demonstrated in neutrophils, 
eosinophils, basophils, monocytes, erythrocytes, megakaryocytes, 
and B lymphocytes from patients with this disease [10-19]. 
Although it has not been conclusively demonstrated, its presence 
is strongly suspected in T lymphocytes derived from the neo¬ 
plastic clone [20]. A possible explanation for the difficulty 
demonstrating the Ph' chromosome in T cells is the fact that the 
majority of peripheral blood T lymphocytes are long-lived cells 
which have matured prior to the occurrence of the neoplastic 
transformation. Any clonal leukemic T lymphocytes are therefore 
young and constitute only a small portion of the total 
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Figure 1. Clonal origin of human hematopoietic cells in chronic 
myelogenous leukemia. This schematic representation is based on 
the results of cytogenetic and G6PD isoenzyme studies. A plus 
sign indicates that the cell has been difinitively shown to be 
involved in the leukemic clone, a question sign indicates that it 
is suspected of being involved, and a minus sign indicates that 
it has not been found to be involved in the leukemic clone based 
on these studies. These results indicate that the leukemic trans¬ 
formation most likely occurs at the level of the pluripotent 
hematopoietic stem cell. BFU-E denotes erythrocyte burst-forming 
unit, CFU-E erythrocyte colony-forming unit, CFU-C myeloid- 
monocytic colony-forming unit, CFU-EO eosinophil colony-forming 
unit, and CFU-MEGA megakaryocyte colony-forming unit. [From 
Koeffler and Golde, ref. 3] 
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T-lymphocyte pool. Hence they are largely undetectable by present 
methods. The Ph' chromosome is not present in somatic cells or 
bone marrow fibroblasts [21]. Since leukemogenesis is believed to 
occur as a sequence of oncogenic events in a single cell [22], 
the presence of this abnormal chromosome in most, if not all, 
hematopoietic cell lines strongly supports the hypothesis that 
the transforming event in CML occurs at the pluripotent stem cell 
level. 
The Ph' chromosome arises from translocation of the long arms 
of chromosomes 9 and 22 in approximately 90% to 95% of patients 
with Ph'-positive CML. Studies carried out over the past few 
years on the 9;22 Ph' translocation have shown that the proto¬ 
oncogene c-abl lies on chromosome 9 close to the translocation 
breakpoint and is brought to chromosome 22 during translocation 
[23-25]. The breakpoint on chromosome 22 usually occurs within a 
specific region designated the breakpoint cluster region, bcr 
[26,27]. The standard translocation is described as t(9;22) 
(q34.1;qll.21) and results in the creation of a hybrid gene 
containing bcr sequences at its 5' end and c-abl sequences at its 
3' end [23,24,26,28]. In approximately 5% to 10% of Ph'-positive 
CML patients different translocations have been identified, e.g. 
t(12;22), t(15;22), and t(17;22) [29]; all, however, produce a 
hybrid bcr-c-abl gene, indicating a complex cryptic translocation 
somehow involving both chromosomes 9 and 22. The product of this 
chimeric gene, a protein with strong tyrosine kinase activity, is 
thought to play a central role in the pathogenesis of CML [30- 
34]. Evidence for this role comes from the strong association 
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between CML and chromosomal translocations involving the bcr of 
chromosme 22, presumed to produce a bcr-c-abl gene. Further evid¬ 
ence comes from the observation that the viral homologue (v-abl) 
of the c-abl protooncogene is responsible for lymphoid leukemias 
induced by the Abelson murine leukemia virus and also produces a 
protein with strong tyrosine kinase activity [35-36]. 
In addition to the cytogenetic evidence, the clonal nature of 
CML is strongly suggested by G6PD isoenzyme analyses of hemato¬ 
poietic cells from female CML patients heterozygous at the X- 
linked G6PD gene locus. A monoclonal pattern of G6PD isoenzyme 
expression has been identified in granulocytes, mono¬ 
cytes/macrophages, erythrocytes, megakaryocytes, and B lympho¬ 
cytes obtained from individual patients [10,11,17,18]. A mono¬ 
clonal pattern has been difficult to show in mature T lympho¬ 
cytes, the explanation again being the low turnover rate of these 
cells. Nevertheless, the presence of a single G6PD isoenzyme in 
all proliferating hematopoietic cell lines, except for T cells, 
in each of the heterozygous female patients suggests a common 
origin for these cells and hence supports the clonal stem cell 
theory of the disease. 
II. Clinical Course of CML 
The course of CML is divided into two phases, an initial 
indolent chronic phase lasting an average of three years, 
followed by an aggressive terminal acute leukemia, termed blast 
crisis. The chronic phase is characterized by excessive prolifer¬ 
ation of granulocytes (neutrophils, eosinophils, and basophils) 
in all patients, megakaryocytes in most patients, and erythro- 
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cytes in some patients [1,2]. Myeloid proliferation may be 
extreme, accounting for 85% to essentially 100% of total marrow 
cells, with total occupancy of all marrow space and myeloid cell 
counts in excess of 1,000,000 per uL in the peripheral blood. The 
underlying defect accounting for this unchecked expansion is 
presumed to be failure of transformed pluripotent hematopoietic 
stem cells to respond normally to feedback regulation [37-39]. 
They continue to proliferate and differentiate into lineage- 
committed stem cells (e.g. myeloid, megakaryocytic, and erythroid 
colony-forming cells) long after exceeding the cell density limit 
at which normal stem cells cease to proliferate. With loss of 
control at the stem cell level, leukemic cells have a growth 
advantage over normal stem cells and their progeny. Leukemic 
cells in the chronic phase retain their capacity to differentiate 
into mature end cells with essentially normal function. An impor¬ 
tant consequence of this normal differentiation during the chron¬ 
ic phase is that patients usually do not suffer from neutropenia, 
thrombocytopenia, or severe anemia and their respective con¬ 
sequences, and hence chronic CML may pass undetected. 
Another characteristic of leukemic cells in the chronic phase 
is a tendency to undergo further neoplastic transformation with 
at least partial loss of the ability to differentiate [40]. As 
the chronic phase of CML progresses, a small percentage of 
patients enters an accelerated stage of the chronic phase, 
characterized by an increased rate of cell division, partial 
blockage of differentiation, and increasing resistance to therapy 
[41]. But in the majority of patients, after an average period of 
three to three and a half years, the disease directly evolves 
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into blast crisis. This phase is characterized by proliferation 
and accumulation in both bone marrow and peripheral blood of 
immature blast cells which fail to differentiate normally. These 
blast crisis cells represent an immature subclone within the Ph'- 
positive leukemic clone [42], This new population of blasts often 
demonstrates additional chromosomal abnormalities, such as a 
second Ph' chromosome, trisomy 8, 19, or 21, and isochrome 17; 
they may also lack the Ph' chromosome [43-45]. These blasts have 
a growth advantage over both normal cells and chronic phase Ph'- 
positive clones; this advantage is due to their failure to mature 
into functional end cells and be removed from the proliferating 
pool. Hence they accumulate in the bone marrow, saturate the 
peripheral blood, and may spill over into extramedullary sites. 
Blast crisis typically behaves like a de novo acute leukemia; 
cells are extremely resistant to therapy, and patients usually 
die within few months. 
Up until the beginning of the last decade it was believed 
that CML blast crisis always involved transformation in the 
myeloid cell line. It is now believed that blastic transformation 
can occur in all hematopoietic cell lines. In each individual 
patient, however, only one cell line is usually involved. On the 
basis of morphologic studies it is now clear that the majority of 
blastic transformations, 60-75%, are myeloblastic while up to 30% 
are lymphoblastic [46-50]. Blast transformations in the remaining 
cell lines — megakaryocytic, monocytic, erythrocytic, eosino¬ 
philic and basophilic — make up less than 5% of the total [51— 
54]. 
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The first suggestion that certain patients in blast crisis 
have a lymphoblastic transformation came in 1971 when it was 
noted that about a third of patients in blast crisis responded to 
treatment with vincristine and prednisone, agents often effective 
in acute lymphoblastic leukemia (ALL) but not acute myeloblastic 
leukemia (AML) [55,56]. In 1974 it was observed that approximate¬ 
ly one third of patients in blast crisis have blast cells with 
lymphoid morphologic characteristics including a high nuclear to 
cytoplasmic ratio, one or two nucleoli, a ’’smudged" nuclear 
chromatin pattern, prominent nuclear folding, and scant baso¬ 
philic cytoplasm without granulation [46-49]. Subsequently, it 
was found that several heterologous antisera developed against 
common type ALL cells reacted with blast cells in about a third 
of cases of blast crisis [57-61]. These antisera did not react 
with mature T or B lymphocytes, myelocyte progenitors, or leukem¬ 
ic cells in the majority of patients with AML. Moreover, the 
majority of blast crisis cells with lymphoid morphology and 
common ALL antigen (CALLA) positivity were also found to contain 
high levels of terminal deoxynucleotidyl transferase, TdT, an 
enzyme that catalyzes the polymerization of deoxynucleoside tri¬ 
phosphates and is found predominantly in cortical thymocytes and 
normal and neoplastic immature lymphoid cells of both T and B 
cell lineage [62-66]. By the late 1970s, this combination of 
findings provided convincing evidence that blast crisis involved 
cells of lymphoid lineage in about one-third af CML patients in 
blast crisis. 
Over the past ten years, three lines of evidence have con¬ 
vincingly demonstrated that the majority of lymphoid blast crises 
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involve cells of B lineage. First, with the development of 
monoclonal antibodies, it was shown that most crisis cells with 
lymphoid morphology present cell surface antigens specific for B 
lymphocytes or their progenitors [67,68]. In addition, cytoplasm¬ 
ic immunoglobulin M (IgM) heavy chain has been demonstrated in a 
number of cases of blast crisis in which the blast cells were 
also CALLA-positive, contained high levels of TdT, and had lymph¬ 
oid morphology [69,70]. Finally, and most convincingly, studies 
carried out over the last few years have demonstrated that in the 
majority of cases of blast cells with lymphoid morphology there 
is in leukemic cells rearrangement of the gene complex coding for 
the Ig heavy chain, a process mandatory in the early development 
of B lymphocytes [71,72]. 
The involvement of T-lymphocyte precursors in the blastic 
transformation of CML has been more difficult to establish [70]. 
Although recent immunophenotyping studies in blast crisis have 
yielded few cases of possible T-cell lineage, the question has 
remained unsettled because of the lack of universally accepted 
specific cell surface markers of T-cell lineage [34,73-77]. 
Recently, the structure of the gene loci encoding the alpha, 
beta, and gamma chains of the T-cell antigen-specific receptor 
(TCR) has been elucidated [78], and molecular probes for these 
genes have become available [79,80]. Moreover, it has become 
clear that rearrangement of these genes is mandatory for the 
development of mature T lymphocytes [81]. Hence, it should now be 
possible to assess clonality of T cells and resolve the question 
of T-cell involvement in CML blast crisis using a combination of 
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TCR gene rearrangement and cell surface antigen analyses. 
III. Molecular Genetic Approach to Clonality in CML 
The molecular approach to the determination of clonality in 
lymphoproliferative diseases is based on the fact that Ig and TCR 
genes in their germ-line forms are composed of discontinuous 
genetic elements separated by non-coding segments of DNA [78]. As 
noted above, rearrangement of Ig genes is mandatory in B-cell 
maturation, and rearrangement of TCR genes is mandatory in T-cell 
maturation [81-83]. These unique rearrangements are the genetic 
basis for the diversity and specificity of both B- and T-cell 
mediated immunologic processes. In molecular terms, these rear¬ 
rangements come about as a result of deletions of non-coding 
segments of DNA and covalent linkage of discontinuous genetic 
elements. With these rearrangements come alterations in the 
locations of restriction endonuclease sites. Thus, Southern 
hybridization analysis can be used to distinguish the rearranged 
from the germ-line forms of these genes. The germ-line form of Ig 
and TCR genes is present in nonlymphoid cells and very early 
lymphoid precursors and may be present in one allele of the genes 
in lymphocytes. In a polyclonal B-cell proliferation, each cell 
undergoes a unique Ig heavy chain gene rearrangement but the 
total cell population contains many different rearrangements. 
Each specific rearrangement gives rise to a restriction fragment 
of unique length, but since each such fragment is present in only 
a single copy, none of these gene fragments can be detected as a 
new band on Southern blots because the method lacks the necessary 
sensitivity. In contrast, all cells in a monoclonal proliferation 
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have the same rearrangement, giving rise to a single new fragment 
in a concentration adequate for identification as a new band on 
Southern blots. Sometimes two new bands appear because of differ¬ 
ent rearrangements of both alleles of the gene. This molecular 
genetic method for assessing the clonality of lymphoproliferative 
disorders is sufficiently sensitive to detect a clonal prolifera¬ 
tion representing 1-5% of a mixed population of cells [84-86]. 
The family of genes coding for the immunoglobulin polypep¬ 
tides is composed of genes located on three chromosomes: genes 
coding for the two light chains, kappa and lambda, on chromosomes 
2 and 22 respectively, and the heavy chain gene locus on chromo¬ 
some 14. The heavy chain gene complex in its germ-line form is 
composed of discontinuous gene subsegments consisting of multiple 
variable regions, V^, diversity regions, D^, joining regions, J^, 
and constant regions, C (Figure 2) [87]. Each one of these re¬ 
gions is a coding segment separated from other segments by non¬ 
coding DNA. The constant regions consist of mu, delta, gamma, 
alpha, and epsilon regions corresponding to the various classes 
of Ig heavy chain — IgM, IgD, IgG, IgA, and IgE respectively 
[88], The germ-line organization of the loci coding for the kappa 
and lambda light chains is similar to that of the heavy chain, 
except for the absence of D regions and presence of a single 
constant region [89,90]. During the development of a mature B 
lymphocyte there is a hierarchy of Ig gene rearrangements whereby 
the heavy chain gene rearrangement preceeds that of the light 
chain, and the kappa light chain gene complex rearranges before 
the lambda gene complex [91-93]. Rearrangement of the heavy chain 
genes begins with the juxtaposition of a single DH region with a 
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Figure 2. A schematic representation of the germ-line arrangement 
and subsequent assembly of the immunoglobulin (Ig) heavy chain 
gene complex. It is composed of multiple VH regions each with its 
own leader (L) sequence, numerous DH regions, six JH regions, and 
only one Cmu region per allele. During the development of a 
mature B lymphocyte VH, DH, and JH regions are covalently joined 
together by deletion of intervening DNA to form a single V-D-J 
segment. The resultant gene is transcribed, and the remaining 
intervening sequence (IVS) and JH regions are removed at the RNA 
level. The mu-mRNA is then translated into the cytoplasmic form 
of mu heavy chain polypeptide. [From Korsmeyer et al, ref. 93] 
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single and then a region with the new D-J segment. This 
process randomly assembles the gene (V-D-J) coding for the 
variable segment of the heavy chain polypeptide and uniquely 
determines its specificity (Figure 2) [82,94-98]. The first class 
of Ig polypeptides produced is IgM, with the constant region 
coded for by the Cmu region. Because this heavy chain gene rear¬ 
rangement does not involve the DNA segment between the cluster of 
J„ regions and the C region, it can be detected with a cDNA 
probe to either or (Figure 3). Rearrangement of light 
chain genes occurs by a process similar to that of the heavy 
chain genes [89,90]. Since every maturing B lymphocyte undergoes 
a unique rearrangement of the heavy and light chain genes, 
detection of a specific rearrangement in a population of lymphoid 
cells not only suggests B-cell lineage but also proves the 
clonality of these cells, as discussed previously [84]. Further¬ 
more, the hierarchy of heavy and light chain gene rearrangements 
permits the determination of the stage of maturation of a B- 
lymphoid clone by analysis of the arrangement of heavy and light 
chain genes [91,93]. 
The TCR has recently been shown to be a heterodimer consist¬ 
ing of alpha (TCRA) and beta (TCRB) subunits [99]. Similar to the 
Ig family of genes, the genes encoding these subunits undergo 
somatic rearrangement in the course of T-lymphocyte development 
[86]. The TCRB gene in its germ-line form is also composed of 
noncontiguous gene segments consisting of a large number of 
variable regions, anc* duplicate sets of diversity, 
and joining, , gene segments separated by the first of two 
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Figure 3. A. Schematic diagram of the germ-line arrangement of a 
portion of the Ig heavy chain gene complex depicting the loca¬ 
tions of Eco RI (E) and Bam HI (B) restriction sites in the 
vicinity of the Cmu region. Also shown are cDNA probes for JH and 
Cmu. It is clear that hybridization with either one of these 
probes would detect a single Bam HI fragment of approximately 18 
kb. As shown, the JH region consists of six exons (dark segments) 
and numerous pseudogenes (psi), and the Cmu region consists of 
four exons. The Cmu cDNA probe used in this study contains the 
first three exons of Cmu [97]. [From Korsmeyer et al, ref. 93] 
B. Schematic diagram of the germ-line arrangement of the TCRB 
gene complex showing the locations of Eco RI (E), Bam HI (B), Sac 
I (S), and Hind III (H) restriction sites. In its germ-line 
configuration, the TCRB gene complex consists of multiple vari¬ 
able (Vbeta) regions each with its own leader sequence (L), and 
duplicate sets of diversity (Dbeta) and joining (Jbeta) regions 
seperating two constant regions (Cbeta-1, and Cbeta-2). This map 
demonstrates that the two Cbeta regions would be present on a 
single 23 kb Bam HI fragment, on two Eco RI fragments of 4 and 11 
kb, and on three Hind III fragments of 3.5, 6.5, and 8.0 kb. As 
shown, the TCRB cDNA probe used in this study contains V, D, J, 
and C regions [79]. [From Waldmann et al, ref. 84] 
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constant regions, ^beta-1 anc* ^beta-2 (figure 3) [100-102]. 
Analogous to that of the Ig heavy chain genes, the process of 
rearrangement of the TCRB genes produces a V-D-J segment 
seperated from one of the constant regions by noncoding DNA 
[103]. The organization of the TCRA genes is similar to that of 
the Ig light chain genes with one constant region and no diver¬ 
sity regions [104]. In addition to the TCRA and TCRB genes, a 
third gene complex, TCRG, has been identified in T cells [105]. 
This gene complex, whose polypeptide product is closely asso¬ 
ciated with but not a part of the TCR heterodimer, has many 
properties in common with TCRA and TCRB genes, including assembly 
from gene segments resembling V, J, and C regions, rearrangement, 
and expression in T lymphocytes [106]. Also similar to the Ig 
family of genes, there is a hierarchy of TCR gene rearrangements. 
TCRG genes rearrange first followed by TCRB and then TCRA genes 
[107]. Therefore, analysis of the arrangement of these genes 
allows the determination of lineage, clonality, and stage of 
maturation of suspected T-lymphoid proliferations [108-111]. 
IV. Aims of the Study 
This thesis is an application of these recent developments in 
the molecular genetics of Ig and TCR genes to the study of 
lymphocyte lineage and clonality in the chronic and blast crisis 
phases of CML. Specifically, its purposes are three-fold: 
1. To look for TCRB gene rearrangements in CML blast crisis and 
to see if T-cell blast crisis can be identified on the basis 
of T-cell surface markers and rearrangement of the TCRB 
genes. 
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2. To see if impending lymphoid blast crisis can be identified 
during the chronic phase of CML by the detection of clonal 
Ig and/or TCR gene rearrangements. 
3. To look for clinical-molecular correlations in subgroups of 
CML patients in lymphoid blast crisis. 
V. Significance 
The detection of T-lymphocyte involvement in the blast crisis 
of CML is important for three reasons: 
1. It would confirm the pluripotent stem cell theory of CML; 
2. It would support the bone marrow stem cell theory of the 
origin of T lymphocytes; and 
3. It would allow for the identification of specific clinical 
features in this subgroup of patients. 
At the time this work was undertaken, there had been no 
reports of the application of TCR gene rearrangement analysis to 
the question of T-cell involvement in the blast phase of CML. 
The second aim of this study is of extreme practical import¬ 
ance. It is generally agreed that the only means presently avail¬ 
able for curing CML is bone marrow transplantation from a histo- 
compatible donor [112]. Moreover, present data suggest that 
patients transplanted before the onset of blast crisis have a 
better chance of being cured than patients transplanted in crisis 
or in remission from crisis. However, in a practical sense, the 
question of when to perform a bone marrow transplantation is not 
easy to answer. Specifically, it is quite easy to reduce leukemic 
burden during chronic phase. Once tumor load is controlled with 
chemotherapy, chronic CML patients are usually asymptomatic, and 
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this state of well being can be maintained for about three years 
in the average patient and substantially longer in some patients. 
Furthermore, bone marrow transplantation is not a benign pro¬ 
cedure. Patient undergoing transplantation may die during or 
immediately post-trasplantation or may suffer from long-term 
complications of transplantation, e.g. graft vs. host disease and 
opportunistic infections. Ideally, clinicians try to maintain 
patients in chronic phase for as long as possible with chemo¬ 
therapy and recommend transplantation when cells begin to show 
increasing resistance to therapy. Therefore, an objective marker 
of incipient blast crisis is needed to guide in choosing the most 
opportune time for transplantation. The identification of a clone 
of lymphoblasts with rearrangement of Ig or TCR genes during the 
chronic phase of disease, making up as few as IX of leukemic 
cells and not recognizable on morphologic examination, would 
signal the incipient onset of blast crisis and argue strongly and 
objectively for early bone marrow transplantation. At the time 
this study was initiated, only few patients had been tested in 
chronic phase for Ig gene rearrangement [73,74], all with 
negative results, and none had been studied for rearrangement of 
TCR genes. 
The issue of possible molecular-clinical correlations was 
suggested by the previously mentioned observation that most 
patients with lymphoid blast crisis have an initial response to 
vincristine and prednisone. In contrast, non-responding patients 
with lymphoid blast crisis have a stormy course with no or little 
response to other forms of therapy. It thus seemed reasonable to 
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inquire if there is an underlying genetic basis explaining this 
variability in the course of lymphoid blast crisis. 
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METHODS AND MATERIALS 
I. Patients and Leukemic Cells 
Leukemic cells were obtained from forty CML patients. All but 
one had Ph'-positive CML, and they all had peripheral blood white 
cell counts in excess of 25,000 per uL at the time cells were 
obtained. Thirty-three samples were from patients in the chronic 
phase of disease, including four in the accelerated stage of the 
chronic phase. Eight samples were from patients in blast crisis, 
four in myeloid and four in lymphoid crisis. The diagnosis of 
blast crisis was based on finding of greater than 30% blasts in 
the bone marrow. Type of crisis was based on morphologic, histo- 
chemical and immunophenotyping studies performed on either peri¬ 
pheral blood or bone marrow leukocytes. Most chronic phase 
samples were obtained at diagnosis, but some were obtained later 
in the course of the disease. In few cases sequential samples 
were obtained. 
Virtually all samples used in the study were buffy coat 
preparations obtained from peripheral blood. These were obtained 
by spinning heparinized blood at 2,000 rpm for 15 minutes and 
carefully removing the layer of white cells with a Pasteur 
pipette. The number of cells collected was estimated from the 
amount of spun blood and the peripheral white cell count, 
assuming 75% recovery. Certain cell samples were obtained by 
leukopheresis of peripheral blood. One sample was from spleen 
removed at surgery. 
Clinical information on patients was obtained from hospital 
records and physicians caring for patients. 
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II. Special Laboratory Studies 
All special laboratory studies were performed in clinical 
laboratories at the Yale-New Haven Medical Center and the Univer¬ 
sity of Alabama Medical Center, Birmingham. Cell surface marker 
studies were performed using a panel of monoclonal antibodies 
directed against CALLA, surface immunoglobulins and other B-cell 
antigens, T-cell antigens, and myelocyte/monocyte antigens. TdT 
enzyme assays were performed on peripheral blood or marrow smears 
by immunofluorescence. Cytogenetic studies were performed by 
standard procedures. 
III. Isolation of DNA 
Genomic DNA was extracted from control and leukemic cells by 
modification of the procedure of Gross and Bellard et al [113]. 
DNA for negative controls was prepared from human placentas and 
normal skin fibroblasts. DNA for positive controls was prepared 
from Molt-3 (a T-cell leukemic cell line) and from lymphomatous 
tissue obtained from two patients with suspected T-cell 
lymphomas. 
Cell pellets frozen in liquid nitrogen were ground to a fine 
powder in a mortar and pestle. The powder was then suspended in 
TNE-A buffer (lOmM Tris Cl/lOmM NaCl/lOmM EDTA, pH 8.0; 2 ml for 
7 
every 1 X 10 cells). Proteinase K and Na dodecyl sulfate (SDS) 
were then added sequentially to final concentrations of 50 ug/ml 
and 0.5% respectively. Each suspension was incubated 3-6 hours at 
37 degrees C with gentle shaking. The viscous suspension was then 
extracted twice with equal volumes of phenol saturated with TNE-B 
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(500mM Tris Cl/lOmM NaCl/lOmM EDTA, pH 8.0), and the aqueous 
phases, containing DNA, were removed with a wide bore Pasteur 
pipette. DNA was then precipitated with 2.5 volumes of chilled 
ethanol and removed from suspension by spooling it onto a glass 
rod. Excess ethanol was removed by rubbing the DNA against the 
inside of an inverted Eppendorf tube. After complete drying, the 
DNA was dissolved in TNE-C (50mM Tris Cl/lOmM NaCl/lOmM EDTA, pH 
8.0; 2 ml for every 1 X 10^ cells) by gentle overnight shaking at 
37 degrees C. DNA was then digested with pancreatic RNAse 
(40ug/ml) at 37 degrees for one hour with constant shaking. After 
complete digestion, the solution was extracted twice with equal 
volumes of phenol/TNE-B and then dialyzed against 100 volumes of 
sterile TNE-D (lOmM Tris Cl/lOmM NaCl/0.5mM EDTA, pH 8.0) using 
5-6 changes of buffer with a minimum of three hours per change. 
After dialysis, the concentration of DNA was determined by 
absorbance at 260 nanometers. It was then stored at 4 degrees C. 
IV. Southern Hybridization 
Genomic DNA samples were digested with restriction endo¬ 
nucleases Eco RI, Bam HI, Hind III and Sac I (obtained from New 
England Biolabs, Beverly, MA, and International Biotechnologies 
Inc., New Haven, CT) under conditions specified by the suppliers. 
For each sample, approximately 15 ug of DNA was digested with 45- 
75 units of enzyme, the excess of enzyme added to insure complete 
digestion. Reaction mixtures were incubated at 37 degrees C for 
16-20 hours after which digested DNA was precipitated by addition 
of l/10th volume of 3.0M Na acetate, pH 7.0, and two volumes of 
chilled ethanol. To insure complete precipitation, the suspension 
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was cooled to -20 degrees C for 2 hours. DNA was then centrifuged 
down in a table-top Eppendorf centrifuge and the liquid phase was 
discarded. After complete drying, DNA was dissolved in 50 ul O.lx 
TE buffer (TE: lOmM Tris-HCl/lmM EDTA, pH 7.4) by vigorous vor- 
texing and then allowed to stand for one hour to insure complete 
solution. Five uL of a dye solution containing 0.2% bromphenol 
blue and 20% glycerol in O.lx TE buffer was then added to each 
DNA sample, and the DNA was size-fractionated by electrophoresis 
on an 0.8% agarose gel made in TAE buffer (40mM Tris acetate/lmM 
EDTA, pH 8.0). A Hind III digest of lambda phage DNA (Boehringer 
Mannheim Biochemicals, Indianapolis, IN) was run on each gel to 
provide size markers. Electrophoresis was carried out at 35-50 
volts for 14-20 hours to obtain 15 cm migration of the bromo- 
phenol blue dye front. After electrophoresis was completed, the 
gel was stained in a solution of ethidium bromide, 0.5 ug/mL, for 
10 minutes, and then photographed with a UV lamp to ascertain 
complete digestion of DNA samples and migration of size markers. 
Following an additional 10 minutes of UV exposure, the gel was 
immersed in 300 ml HC1 solution (21.5 mL concentrated HC1 in 1 L 
solution) for 10 minutes twice with constant shaking. After 
washing three times with distilled water, the gel was immersed 
twice in 300 mL of denaturing solution (0.5 M NaOH/1.5 M NaCL) 
for 25 minutes each time with constant shaking. Again after 
washing three times with distilled water, the gel was immersed in 
300 mL of neutralizing solution (1M Tris C1/1.5M NaCl, pH 8.0) 
for 25 minutes each time, also with constant shaking. Denatured 
DNA was then transferred to nitrocellulose filter paper (Type BA, 
45 micrometer porosity, Schleicher and Schuell) previously pre- 

22 
wetted for 5 minutes with distilled water, using the method of 
Southern [114]. Transfer of DNA was carried out for approximately 
20 hours using lOx SSC (20x SSC: 3.0M NaCl/0.3M Na citrate) as 
the transfer solution. After transfer, the nitrocellulose paper 
was rinsed with 6x SSC and allowed to dry in room air. It was 
then baked in a vacuum oven for 2 hours at 80 degrees C. After 
cooling the nitrocellulose paper was soaked for 6 hours at room 
temperature with constant shaking in a solution consisting of 5x 
Denhardt's solution (lOx stock solution containing 5 gm Ficoll, 5 
gm polyvinylpyrrolidone, 5 gm bovine serum albumin-Pentax frac¬ 
tion V, and water up to 500 mL) and 6x SSC. The nitrocellulose 
paper was then prepared for hybridization by incubation at 37 
degrees C for 1 1/2 hours in lx Denhardt's solution, 50% deion¬ 
ized formamide, and 4x SSC. It was then hybridized with the 
appropriate denatured radioactive probe in a mixture of lx 
Denhardt's solution, 50% formamide, 4x SSC, 0.20% SDS, and 10 
ug/mL denatured salmon sperm DNA (50 uL of hybridization fluid 
per squared cm of nitrocellulose paper). The probe and salmon 
sperm DNA were denatured immediately before addition to the 
hybridization mixture by immersion in a boiling water bath for 5- 
10 minutes and then quenching in a dry ice-ethanol mixture. 
Hybridization was carried out for 36 hours at 37 degrees C with 
constant shaking. Maximal contact between the hybridization 
solution and the nitrocellulose paper was facilitated by placing 
the paper in a plastic bag in which the solution has been placed 
and meticulously excluding all air bubbles. The bag was then 
sealed and placed in another plastic bag containing a large 
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volume of water and air. After hybridization, the filter paper 
was washed 4 times, 15 minutes each time with 2x SSC/0.1% SDS 
solution at room temperature, followed by 2 washings with 0.25x 
SSC/0.1% SDS at 64 degrees C, the first washing for 2 1/2 hours 
and the second for a half hour. The filter paper was allowed to 
dry and then autoradiographed for 1-7 days at -70 degrees C using 
Kodak XAR-5 X ray film and a Dupont Chronex intensifying screen. 
V. Probes 
Three human DNA probes were used in this study: an Ig heavy 
chain probe, a TCRB probe, and a bcr probe. The Ig probe was a 
1.3 kb Eco RI cDNA fragment containing the first three exons of 
the mu constant region (Cm(j) of the heavy chain gene complex 
(Figure 3) [106]. This probe was kindly supplied by Dr. P. J. 
Buckley of the Department of Pathology. It was prepared from a 
plasmid originally provided by Dr. P. Leder, Harvard Medical 
School, Boston. 
The TCRB probe was a 770 bp cDNA segment obtained from mRNA 
of the Jurkat-2 cell line, a T-cell leukemic line [103]. It 
contains V, D, J, and C regions of the TCRB gene (Figure 3). The 
complete sequence of this probe has been determined [79]. The 
plasmid was originally provided to Dr. Paul Lebowitz by Dr. Tak 
Mak of the Ontario Cancer Institute, Toronto. The probe was 
inserted at the unique Pst I site in pBR322. 
A large scale preparation of plasmid pBR322 containing the 
TCRB probe was provided by Dr. Lebowitz. The plasmid (420 ug of 
DNA) was digested with the restriction enzyme Pst I (New England 
Biolabs) according to the supplier's recommendations. The diges- 
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tion mixture was size-fractionated by electrophoresis on a 1% 
agarose gel in lx TAE buffer. Following ethidium bromide stain¬ 
ing, two distinct bands were seen under UV light, the one at 
approximately 800 bp corresponding to the cDNA insert. This band 
was excised from the gel and placed in a segment of dialysis 
tubing with lx TAE buffer. The DNA was then electroeluted in an 
electrophoresis apparatus using 100 volts for 3 hours. Polarity 
was reversed for 5 minutes at the end of the electroelution in 
order to elute DNA from the dialysis bag. Solid NaCl was then 
added to the DNA solution to a final concentration of 0.2 M. The 
DNA was then chromatographed on an Elutip-DNA column (Schleicher 
and Schuell) using salt elution according to the supplier's 
instructions. After completion of chromatography, the DNA was 
precipitated by adding 2 volumes of ethanol. DNA was then re¬ 
covered by centrifugation, allowed to dry, and dissolved in 50 
uL of water. The concentration of DNA was estimated by small 
scale agarose-ethidium bromide electrophoresis with a cDNA probe 
of similar size and known concentration, followed by comparison 
of fluorescence under UV light. 
The probe for the bcr of chromosome 22 was a 1200 bp Bgl II/ 
Hind III fragment purchased from Oncogene Science Inc. (Mineola, 
NY). 
All three probes were radiolabeled by incorporation of radio¬ 
active dCTP and dGTP into the double stranded DNA by the method 
32 
of nick translation. Radioactive alpha-P -dCTP and -dGTP (both 
with specific activities of 3000 Ci/mmol) were obtained from 
Amersham Inc. (Arlington, IL). Nick translation reactions 
contained, in a total volume of 22 uL, lx nick translation buffer 
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[113], 1 nmole each of dATP and dTTP, 70 uCi of P^-dCTP and 
32 P -dGTP, 1 ug probe, and 3 uL of premixed E. coli DNA polymerase 
and pancreatic DNAse (Boehringer Mannheim). The reaction mixture 
was incubated for 2 hours at 15-16 degrees C after which the 
reaction was terminated by addition of 4 ul of 0.2M EDTA, pH 8.0. 
The radioactive probe was isolated by chromatography through a 
Sephadex G-100 column, using lx TE buffer for elution. Total 
counts of radioactivity were determined by scintillation counting. 
8 Probes were labeled to specific activities of 1-2 X 10 cpm/ug 
DNA. For hybridization, 1-5 X 10^ cpm of probe were used for 
every mL of hybridization fluid. 
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RESULTS 
I. Chronic Phase CML 
Thirty-three patients were studied in the chronic phase of 
CML, including four in the accelerated stage. None of these 
patients showed rearrangement of either the Ig heavy chain or the 
TCRB genes. 
Figure 3 schematically depicts the structure of a portion of 
the Ig heavy chain gene complex. As shown, there are two Bam HI 
restriction sites in the vicinity of the C region, one 5' to 
the Jjj region and the other 3' to the Cmu region. Digestion of 
germ-line DNA with Bam HI should yield an approximately 18 kb 
restriction fragment that includes both Cmu and regions. A 
rearrangement bringing and segments 5' to a segment 
removes the existing 5' Bam HI site and brings a new Bam HI site 
5' to the new V-D-J segment, consequently resulting in a new 
restriction fragment length. This fragment is recognized by both 
C and JIT probes since there is no Bam HI site between the C 
mu H ^ mu 
and J„ regions. Therefore, all rearrangements 5' to the C 
n mu 
region would be detected by a Cmu probe in Bam HI digests. 
Figure 4 shows representative Southern hybridization results 
of peripheral leukocyte DNA from chronic phase CML patients 
digested with Bam HI and probed with the C^^ region probe. All 
patients studied demonstrated a single 18 kb Bam HI fragment 
representing the germ-line pattern. 
The structure of the TCRB gene complex is also depicted in 
Figure 3. As shown, there are two constant (Cbeta) regions within 
this gene locus. As expected from the location of restriction 

27 
1 23456 789 10 
wvwVwwii —18kb 
Figure 4. Southern hybridization analysis of peripheral blood 
leukocyte DNA from seven patients with chronic phase CML (lanes 
1-7) and nonleukemic control DNA (lanes 8-10) digested with Bam 
HI and probed with Ig Cmu probe. A single approximately 18 kb 
band appears for both patients and controls. 
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sites, digestion with Eco RI should produce two fragments con¬ 
taining C region sequences, an approximately 11 kb fragment 
containing G^eta-l and an approximately 4 kb fragment containing 
^beta-2 (Figure 5). Occasionally, however, a third fragment of 
approximately 8.5 kb is observed in germ-line DNA. This band was 
originally thought to represent a rare polymorphism within the 
11 kb fragment containing the ^ region. However, this 
explanation is no longer tenable for three reasons: (i) the 8.5 
kb fragment has not been seen in the absence of the 11 kb frag¬ 
ment, which would be expected in a homozygote for the 8.5 kb 
polymorphic fragment; (ii) in one normal individual, the 8.5 kb 
fragment was seen in digests of lymphocyte, but not granulocyte 
DNA [115}; and (ifi) in the case of one patinet from whom serial 
leukemic DNA samples were examined ( patient M.P., Figure 10), 
this fragment was present in some samples (samples 2,3) but 
absent in other samples (samples 1,2). All these findings suggest 
that the 8.5 kb DNA fragment arises from technical factors 
associated with DNA extraction or Southern blotting. 
Figure 3 also indicates that a Cbeta probe also recognizes a 
23 kb Bam HI fragment containing both regions (Figure 5); 
two Sac I fragments, a 6.0 kb fragment containing and a 
5.6 kb fragment containing Cj:)eta_2» and three Hind III fragments, 
the smallest at 3.5 kb containing ^ p and the other two at 
8.0 kb and 6.5 kb containing portions of Cbeta_2* 
Although the TCRB probe used in this study contained V, D, J, 
as well as C regions [Dr. Tak Mak, written communication], and 
although in previously published studies it detected bands 
corresponding to V and C regions [109], it recognized only the C 
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Figure 5. Control Southern hybridization results showing the 
constant region germ-line pattern of the TCRB gene complex, 
hybridization with a TCRB probe reveals a single 23 kb Bam HI 
fragment (odd lanes) containing both Cbeta regions, and two Eco 
RI fragments (even lanes), an 11 kb fragment containing Cbeta-1 
and a 4.2 kb fragment containing Cbeta-2. The 8.5 kb fragment 
appearing in Eco RI digests is thought to contain a portion of 
Cbeta-1. Its unpredictable presence is thought to be an artifact 
of DNA extraction. Control DNA was obtained from human placentas 
and skin fibroblasts. 
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regions in the studies reported here. The most likely explanation 
for this behavior relates to the stringency of the washing con¬ 
ditions employed in Southern hybridization. Both V and J regions 
in assembled V-D-J coding segments involve a large degree of 
variability from one cell to another, variability that is the 
genetic basis of immunologic diversity and specificity. A partic¬ 
ular probe with single V and J segments may thus fail to hybrid¬ 
ize to V and J regions containing highly variable sequences. 
Regardless of what the true explanation may be, the results of 
this study should not be affected. Any rearrangement of the beta 
chain gene complex will assemble a V-D-J coding segment 5' to one 
of the regions and thereby effect an alteration in the 
location of restriction sites 5' to the J region. Since some of 
these endonucleases (notably Eco RI and Bam HI) lack sites in the 
sequence between the J and C regions, the resultant new restric¬ 
tion fragments should therefore be detectable by probes to the 
Cbeta re«ions- 
Figures 6-9 show representative Southern analyses of TCRB 
gene structure in chronic phase CML patients. Studies were 
carried out with four restriction endonucleases: Eco RI, Bam HI, 
Hind III, and Sac I. Germ-line patterns were obtained in all 
cases. 
One of the patients in the accelerated stage of the chronic 
phase, M.P., who later entered a lymphoid blast crisis, had an 
unusual pattern for the TCRB gene on digestion with Eco RI. 
Samples of genomic DNA from one point in the accelerated stage of 
the chronic phase lacked the fragment containing the ta.—2 
region (Figure 10, sample 2). This is felt to be artifactual for 
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Figure 6. TCRB Southern hybridization results of peripheral blood 
leukocyte DNA from six representative chronic phase CML patients 
(lanes 1-12) digested with Eco RI (odd lanes) and Bam HI (even 
lanes). Lanes 13-16 show control results. All chronic phase CML 
patients demonstrated the germ-line pattern. 
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Figure 7. TCRB Southern hybridization results of peripheral blood 
leukocyte DNA from five representative chronic phase CML 
patients, digested with Bam HI. Lanes 1-5 show patient results, 
and lane 6 shows control results. All chronic phase CML patients 
had the 23 kb germ-line fragment. The two extra bands in lane 5 
were not present on repeat digestion, and hence are not 
significant. 
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Figure 8. TCRB Southern hybridization results of peripheral blood 
leukocyte DNA from seven representative chronic phase CML 
patients, digested with Hind III. Lanes 1-7 show patients' 
results and lanes 8-10 show control results. The germ-line 
pattern, shown by the controls, consists of a 3.5 kb fragment 
containing Cbeta-1 and two fragments, 6.5 kb and 8.0 kb, 
containing portions of Cbeta-2. The germ-line pattern appeared in 
genomic DNA samples obtained from all CML patients in this study. 
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Figure 9. TCRB Southern hybridization results of peripheral blood 
leukocyte DNA from eleven representative chronic phase CML 
patients, digested with Sac I. Lanes 1-11 show patients' results, 
and lanes 12-14 show control results. The germ line pattern, 
consisting of a 6.0 kb fragment containing Cbeta-1 and a 5.4 kb 
fragment containing Cbeta-2, was seen in peripheral blood 
leukocyte DNA from all chronic phase CML patients studied. 
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two reasons. The first is that fragments containing C^eta ^ 
appeared in Hind III and Sac I digests of the same DNA, and there 
was no change in the size of the Bam HI fragment which contains 
both C^eta ^ and ta_2 ^ata not shown). Secondly, the C^eta ^ 
fragment appeared in DNA samples obtained from this patient later 
in the course of the disease, both in accelerated chronic phase 
and blast crisis. Furthermore, complete absence of this fragment 
in the presence of a normal ^ fragment can only be 
explained by complete deletion of ^ and presence of normal 
^beta-1’ This is unlikely, not only because such a deletion 
should be present in all enzymatic digests, but also because it 
would be a nonphysiologic deletion that cannot be explained by a 
functional rearrangement. 
II. Myeloid Blast Crisis 
Four patients were studied in myeloid blast crisis. None of 
these patients demonstrated rearrangement of the Ig heavy chain 
genes using Bam HI digestion or the TCRB genes using Eco RI, Bam 
HI, Hind III, and Sac I digestions (results not shown). 
III. Lymphoid Blast Crisis 
Four patients were studied in lymphoid blast crisis. Of these 
patients one, B.S., had rearrangement of the TCRB gene alone; a 
second, E.B., had rearrangements of both Ig heavy chain and TCRB 
genes; while the other two, A.K. and the aforementioned M.P., 
had no detectable rearrangements. 
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Figure 10. TCRB gene analysis of peripheral blood leukocyte DNA 
from patient M.P.. Lanes 1-5 and 7 show Eco RI digests, and lanes 
6 and 8 show Bam HI digests. Four serial samples of DNA were 
obtained in the course of accelerated chronic phase. Sample 1 
(lane 1) obtained early in the accelerated stage, sample 2 (lanes 
2 and 5,6) obtained two months later, sample 3 (lane 3) obtained 
ten months after sample 1, and sample 4 (lane 4) obtained at 
onset of blast crisis, approximately two years after sample 1. 
Lanes 7 and 8 are controls. It is noted that sample 2 DNA lacked 
the band corresponding to Cbeta-2 (arrows). Bands containing 
Cbeta-2 were, however, present in Hind III and Sac I digests of 
sample 2 DNA (results not shown). It is also noted that an 8.5 kb 
Eco RI band appeared in DNA of samples 2 and 3 but was absent in 
DNA of samples 1 and 4. 
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A. Patient B.S. 
Patient B.S., a female, presented at age 29 with a classic 
clinical and laboratory picture of the chronic phase of CML. 
Cytogenetic studies revealed a t(9;22) translocation, and 
Southern hybridization with a bcr probe revealed new bands 
indicating involvement of the bcr in the translocation with pre¬ 
sumed formation of a hybrid bcr-c-abl gene (Figure 11). The 
patient's leukocyte count was initially controlled on daily 
busulfan, but five months after diagnosis she entered blast 
crisis, and nine and a half months after diagnosis she died. 
Laboratory data obtained on entry into blast crisis are shown 
in Table I. The bone marrow was packed with lymphoid-appearing 
blasts, the majority CALLA-positive. In the peripheral blood 76% 
of the white cells were Leu-l-positive, 20% were Leu-2-positive, 
13% were Leu-3-positive, and 24% were 0KT6-positive, all sugges¬ 
tive of T-cell phenotype. Only 10% were B4-positive, indicating a 
small percentage of B cells. Lymphoid blast crisis of probable T- 
cell lineage was diagnosed, and the patient was treated with 
vincristine and prednisone with no response. Table 2 shows labo¬ 
ratory data on two subsequent occasions, three and four months 
after onset of blast crisis. These data show that the percentage 
of total T cells (Leu-l-positive), helper T cells (Leu-3-posi- 
tive), and thymocytes (0KT6-positive) in the periphery rose 
significantly during the course of blast crisis. It was also 
observed that the majority of cells became TdT positive, while 
CALLA-positive cells became weakly positive and then disappeared. 
The percentages of B-lymphoid cells (B1-, B4-, and HB2-posifive) 
and myeloid-monocytic cells (OKMl-positive) were also very small. 
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Figure 11. Breakpoint cluster region (bcr) analysis of leukemic 
blast cell DNA obtained from patient B.S. (PI) and patient E.B. 
(P2). C represents control results. DNA was digested with Bgl II 
(Bg), Hind III (H), Bam HI (B), and Eco RI (E). The appearance of 
new bcr fragments (arrows) in DNA from both patients indicates a 
translocation involving bcr of chromosome 22. 
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Table 1. Clinical and laboratory data of patient B.S. at onset of 
blast crisis. 
Patient: B.S. 
Age: 29 
Sex: Female 
WBC count: 51,000-81,000 (range over 7 days) 
Percentage blasts: 13-37% (peripheral blood) 
Cytogenetics: 46XX, t(9;22) (q34;qll) 
Bone marrow analysis: Immature lymphoid blasts, 
majority CALLA-positive 
Peripheral blood 
cell surface markers: 
(1) T cells: Total T cells (Leu 1) 73% 
T suppressor cells (Leu 2) 20% 
T helper cells (Leu 3) 13% 
Thymocytes (0KT6 Ag) 24% 
SRBC rosettes (Leu 5) 24% 
Natural killer cells 3% 
0KT10 Ag 2% 
(2) B cells: HB2 <1% 
B4 10% 
Surface Ig (M,D,G,A) ( + ) 
Cytoplasmic Ig (M,D,G,A) <1% 
(3) CALLA 76% 
(4) Myeloid/Monocytic 0KM1 Ag 1% 
(5) HLA-DR (-) 
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Table 2. Serial cell surface marker analyses on patient B.S. 
during the course of blast crisis: I. At onset of blast crisis. 
II. Three months after onset of blast crisis. III. Four months 
after onset of blast crisis. 
WBC (peripheral blood) 
Percentage blasts + lymphocytes 
TdT 
Peripheral blood 
cell surface markers: 
(1) T cells 
Total T cells (Leu 1) 
T suppressor cells (Leu 2) 
T helper cells (Leu 3) 
SRBC rosettes (Leu 5) 
Transferrin receptor (Leu 9) 
Thymocytes (0KT6) 
0KT10 
Natural killer cells 
(2) B cells (B4) 
(3) CALLA 
(4) Myelocyte/Monocyte (0KM1) 
(5) HLA-DR 
I. II. III. 
79,000 187,000 80,000 
99% 93% 99% 
( + ) ( + ) 
73% 91% 88% 
20% 3% 23% 
13% 25% 38% 
24% 3% 40% 
100% 73% 
24% 48% 60% 
2% 6% 2% 
3% <. 5% <1% 
10% <.5% <1% 
76% 80% <1% 
1% 1% 4% 
(-) <.5% 1% 
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Peripheral blood drawn three months after the onset of blast 
crisis (corresponding to column II, Table 2) was used for Ig and 
TCR gene rearrangement studies. As shown in Figure 12, no Ig 
heavy chain gene rearrangements were detectable in Bam HI digests 
of the patient's leukemic cell DNA. 
Southern hybridization of the patient's leukemic DNA with the 
TCRB probe revealed a new Eco RI fragment of approximately 5.0 kb 
in addition to the germ-line pattern (Figure 13). However, only 
the germ-line pattern was seen in digestions with Bam HI, Sac I, 
and Hind III (Figure 14). Although the new band on Eco RI diges¬ 
tion suggests a gene rearrangement, the results with the other 
three enzymes make it difficult to be certain of this conclusion. 
However, the alternative explanation, that the new Eco RI band 
represents a partial digestion product, seems extremely unlikely 
for three reasons; (i) Two repeat digestions carried out with a 
considerable excess of new enzyme overnight followed by a second 
addition of a similar amount of enzyme and digestion for 4-6 
additional hours gave identical results, (ii) The same DNA sample 
did not give partial digestion products with Bam HI, Hind III, or 
Sac I, nor did it give partial bcr gene products when digested 
with Bam HI or Hind III. (iii) From the Eco RI cleavage sites on 
the TCRB gene map, it is difficult to explain the production of a 
5.0 kb partial digestion product. The possibility that this 5.0 
kb Eco RI fragment might represent a variable region fragment can 
also be dismissed since none of the sixteen other Eco RI digests 
on the same nitrocellulose paper subjected to the same washing 
conditions showed this band. On the other hand, the possibility 
that the 5.0 kb Eco RI band reflects a genuine rearrangement of 
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Figure 12. Ig heavy chain gene analysis of leukemic cell DNA from 
patients E.B. (lane 1) and B.S. (lane 3). DNA was digested with 
Bam HI and probed with Cmu cDNA. The results show a clear rear¬ 
rangement in DNA from patient E.B. but no detectable rearrange¬ 
ment in DNA from patient B.S.. Lane 2 shows the germ-line pattern 
in control DNA. 
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Figure 13. TCRB gene analysis of Eco RI digested genomic DNA 
obtained from leukemic blast cells from patient B.S. (lane 2) and 
from two suspected T-cell lymphomas (lanes 3 and 4). A new band 
of approximately 5 kb appears in digests from patient B.S. and 
one of the lymphomas (lane 3, bottom arrow). This band most 
likely represents a new fragment containing Cbeta-1. DNA from the 
second lymphoma clearly has a rearrangement 5' to Cbeta-1 as 
suggested by appearance of a new band containing that region 
(lane 4, top arrow). Lane 1 demonstrates the germ-line pattern in 
a control. 
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Figure 14. TCRB gene analysis of DNA from leukemic cells of 
patient B.S. (lanes 3 and 6) and the two suspected T cell 
lymphomas (lanes 1,4 and 2,5) digested with Hind III (Lane 1-3) 
and Sac I (lane 4-6). Although the three samples demonstrated 
nongerm-line Eco RI fragments, as shown in Figure 13, they all 
show germ-line patterns in these digests. 
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the genome is supported by the appearance of an identical Eco RI 
fragment in DNA from a suspected T-cell lymphoma (Figure 13, lane 
3). In addition, examination of the TCRB gene map (Figure 3) 
reveals that a V-D-J rearrangement 5' to C^etawill not be 
detected by a constant region probe in Hind III and Sac I 
digests, because these enzymes possess restriction sites in the 
DNA segment between 3j3eta and ^beta-1* Such a rearrangement may 
also pass undetected in Bam HI digests if it does not produce an 
appreciable change in the lenghth of the 23 kb germ-line 
fragment. Therefore it is quite conceivable that this rearrange¬ 
ment is detectable only by Eco RI digestion. It is also signifi¬ 
cant that in Eco RI digested DNA from a second suspected T-cell 
lymphoma (Figure 13, lane 4) there is a nonambiguous rearrange¬ 
ment involving the ^ band in the presence of germ-line 
pattern with the three other enzymes (figure 14). All these 
arguments suggest that the 5.0 kb band represents a clonal rear¬ 
rangement of the TCRB gene complex in leukemic cells of patient 
B.S.. 
It is interesting that the pattern obtained for patient B.S. 
is identical to that obtained for one of the two suspected T-cell 
lymphomas. This suggests either the presence of a limited 
repertoire of possible rearrangements involving the TCRB genes or 
an association between the development of neoplasia and specific 
patterns of rearrangement [86]. 
B. Patient E.B. 
Patient E.B., age 70, also a female, presented at another 
hospital with a picture of acute leukemia. Her leukemic cells 
s0, 
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were not typed, and she was treated with aggressive chemotherapy 
(daunamycin, cytosine arabinoside and thioguanine) with a tran¬ 
sient remission. During the period of remission both her peri¬ 
pheral blood and bone marrow were typical of CML. Moreover, 
cytogenetic studies performed at this time revealed a t(9;22) 
translocation and Southern analysis carried out later using a bcr 
probe clearly showed new fragments suggesting bcr-c-abl junction 
formation (Figure 11). In view of the typical CML picture in the 
peripheral blood and bone marrow during remission, the 9;22 
translocation, and bcr junction fragments, this patient's most 
likely diagnosis was CML presenting in blast crisis. After her 
brief remission, the patient relapsed. At that time 70-80% of 
bone marrow blasts were TdT-positive, suggesting lymphoid blast 
crisis, but lymphocyte marker studies with Leu 4 and 14 anti¬ 
bodies (pan-T and B cell antibodies) were both negative. Southern 
analyses were undertaken on DNA from leukemic cells obtained 
during this relapse. 
As shown in Figure 15, hybridization with the TCRB probe 
revealed new Bam HI and Hind III bands and deletion of the 11 kb 
Eco RI, 6.5 kb Sac I, and 3.5 kb Hind III germline bands. These 
results clearly indicate rearrangement of the TCRB gene complex 
resulting in a deletion of the Cj3etaregion. Shortening of the 
germ-line Bam HI fragment is also consistent with this interpre¬ 
tation. The new Hind III band, however, is not predicted by this 
interpretation and is most likely the product of a partial diges¬ 
tion. The appearance of normal germline bands corresponding to 
fragments containing sugSests that the genomic rearrange¬ 
ment that resulted in deletion of C, „ . was a considerable beta-1 
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Figure 15. TCRB gene analysis of leukemic cell DNA obtained from 
patient E.B. (P) and digested with Eco RI (E), Bam HI (B), Sac I 
(S), and Hind III (H). C represents results for a normal control. 
Arrows pointing to the right demonstrate absence of the germ-line 
Eco RI, Sac I, and Hind III fragments (11 kb, 6.5 kb, and 3.5 kb, 
respectively) containing Cbeta-1. Arrow pointing left shows a new 
Bam HI fragment of approximately 14 kb containing both Cbeta-1 
and Cbeta-2. The new Eco RI (in control DNA) and Hind III (right¬ 
most arrow) bands were not seen on repeat digestions and there¬ 
fore most likely represent partial digestion products. 
'I _• J 3 £'! , 1 
•'-'fli C- 
i ’ 
•: ’ jr 
d - n 
■30*»ib ' 
■■■' o ' 
OJ " 
■ r ';!/« !T.i' iijod ft 
" 05 lo ' 
48 
distance 5' to C, n and therefore did not alter the locations 
of restriction sites immediately 5' to Cbeta_2* It is interesting 
that the pattern of rearrangement of the TCRB gene in patient 
E.B.'s leukemic cells is identical to that obtained for DNA from 
the Molt-3 T-cell leukemia cell line (data not shown). This also 
supports the hypothesis of a limited number of possible rear¬ 
rangements, or the presence of an association between certain 
rearrangements and the development of leukemia. 
Hybridization studies of patient E.B.'s genomic DNA with the 
Ig Cmu probe also showed a clear rearrangement (Figure 12). On 
Bam HI digestion, a single band of approximately 16 kb appeared 
instead of the germ-line 18 kb band. This pattern was also 
similar to that obtained for the Molt-3 cell line. 
In both TCR and Ig hybridization studies there was complete 
absence of some germ-line bands. This suggests not only that 
peripheral leukocytes were essentially all clonal blasts but also 
that in these blasts there was rearrangement of both alleles. 
Patient E.B. survived only five months after initial 
presentation. 
C. Patients M.P. and A.K. 
The two remaining patients studied in lymphoid blast crisis, 
M.P. and A.K., were also female. Hybridization studies of genomic 
DNA from these patients showed no rearrangement of either Ig Cm(j 
or TCRB genes (Figures 10 and 16). 
It is noteworthy that patient M.P. remained in chronic phase 
for nine years before converting to blast crisis while patient 
A.K. converted after approximately two and a half years. Crisis 
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Figure 16. Southern hybridization results of blast crisis 
leukemic DNA from patients M.P. and A.K.. A. TCRB gene analysis 
of patient M.P. DNA (lanes 1 and 3), patient A.K. DNA (lanes 2 
and 4), and control DNA (lanes 5 and 6) digested with Eco RI 
(lanes 1 and 2) and Sac I (lanes 3-6). Both patients demonstrated 
the germ-line patterns. B. Ig heavy chain gene analysis with Cmu 
probe. Lane 1 shows patient M.P. DNA and lane 2 shows patient 
A.K. DNA. Lane 3 shows the germ-line pattern in a control. There 
are no detectable rearrangements. 
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in M.P. was fatal within one week while A.K. underwent 
marrow transplantation and succumbed to recurrent leukemia 
one year later. 
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DISCUSSION 
Much has been learned about the course and nature of CML 
since its initial description by Minot [116]. A neoplastic trans¬ 
formation occurs at the level of the bone marrow pluripotent 
hematopoietic stem cell with subsequent involvement of granulo¬ 
cytic, erythrocytic, megakaryocytic, monocytic, and lymphocytic 
cell lines. In the chronic phase there is excessive proliferation 
of myeloid cells with retention of their capacity to differen¬ 
tiate. Both cytogenetic and isoenzyme studies provided strong 
evidence of the monoclonal nature of the disorder. At some point 
in the course of the chronic phase, a second oncogenic event 
occurs in an immature lineage-committed cell within the prolifer¬ 
ating clone. As a result of this second transformation, an im¬ 
mature "blastic" subclone emerges with development of the blast 
crisis phase of disease. Approximately one-third of blastic 
clones are of lymphoid lineage, the majority B cells. At the time 
this study was initiated, T-lymphoid blast crisis had not been 
convincingly demonstrated. 
In this study, analysis of Ig heavy chain and TCRB gene 
rearrangements was applied to the study of CML in both chronic 
and blast crisis phases of the disease. Prior studies had looked 
into Ig gene rearrangements in patients with lymphoid blast 
crisis and few patients in the chronic phase of the disease 
[71,72]. Almost all patients (17/18) in lymphoid crisis were 
shown to have an Ig heavy chain gene rearrangement in DNA from 
blastic cells. In contrast, none in chronic phase had demon¬ 
strated Ig gene rearrangements. Prior to this study, there were 
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no reported analyses of TCR gene rearrangements in CML. 
None of the 33 randomly selected chronic phase CML patients 
examined in the present study demonstrated rearrangement of 
either the Ig heavy chain gene or the TCRB gene in peripheral 
blood cells. These results are thus in agreement with those of 
previouly reported small scale studies addressing the issue of Ig 
gene rearrangement [71,72], We may thus conclude that with the 
level of sensitivity used in this study one cannot detect trans¬ 
formed lymphoid clones in the peripheral blood of chronic phase 
CML patients. Hence, one cannot yet use analysis of Ig and TCR 
gene rearrangements to identify early transformation to lymphoid 
crisis and to predict the onset of clinically evident blast 
crisis. 
The present study does not exhaust approaches for identifying 
the early conversion to lymphoid blast crisis by detection of Ig 
and/or TCR gene rearrangements. Improvements in the methods can 
be made by increasing the sensitivity of detection of rearrange¬ 
ments and by employing bone marrow for assay. 
The sensitivity of the methods employed in this study allows 
for the detection of a clone constituting no less than IX of the 
total number of leukocytes [86], Increasing the sensitivity of 
the methods is therefore an obvious way to improve on this study. 
Recently it has become possible to prepare radioactive cDNA 
probes with 5-10 times the specific activity used in this study. 
This method, developed by Feinberg and Vogelstein [117], uses 
binding of random primers followed by primer extention to produce 
radioactively labled cDNA with specific activity as high as 
1 X 10^ cpm/ug DNA. 
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It is also noteworthy that this study made use of peripheral 
blood samples. Since blast crisis begins with an oncogenic event 
in an immature bone marrow cell, and since the transformed clone 
proliferates in the marrow before spilling over into the peri¬ 
pheral blood, it would seem more likely that early conversion to 
lymphoid crisis could be picked up in the marrow rather than 
peripheral blood. Therefore, future attempts to identify Ig and 
TCR gene rearrangements during the chronic phase of CML should be 
directed to the bone marrow. Although it is conceivable that 
marrow studies may suffer from sampling error, they still seem 
more likely to detect the presence of blastic clones than peri¬ 
pheral blood studies. 
Finally, approximately half of the chronic phase samples 
examined in the present study were obtained from patients at or 
shortly after diagnosis. Only four were from patients in the 
accelerated stage of chronic phase and only one of these patients 
went on to develop lymphoid blast crisis. Future attempts to 
demonstrate Ig and TCR gene rearrangements should thus concen¬ 
trate on patients who are well into chronic phase or are begin¬ 
ning to show early signs of progression, for example a require¬ 
ment for higher doses of suppressant drugs. 
None of the four patients studied in myeloid blast crisis 
demonstrated rearrangement of Ig heavy chain or TCRB chain genes. 
Although this result was expected [71,72], analyzing myeloid cri¬ 
sis cells was of potential interest for two reasons: (i) Myeloid 
leukemia cells occasionally demonstrate lymphoid features, e.g. 
lymphoid surface markers or TdT positivity. This is an example of 
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so-called lineage infidelity. (ii) Occasional patients demon¬ 
strate two distinct leukemic cell lines, e.g. one myeloid and one 
lymphoid. The presence of Ig or TCR gene rearrangements in the 
peripheral blood samples of patients with myeloid blast crisis 
would have suggested one of these two possibilities, more likely 
the latter. 
One of the four patients studied in lymphoid blast crisis, 
B.S., demonstrated a germ-line configuration of the Ig heavy 
chain gene but appeared to have a clonal rearrangement of the 
TCRB gene in her leukemic blast cells. In addition, the patient's 
crisis cells demonstrated TdT-positivity, and cell surface marker 
studies detected T-cell surface antigens (monoclonal antibodies 
Leu 1, 2, 3, and 5; 0KT6 Ag; 0KT10 Ag) and virtual absence of B- 
lymphoid and myeloid/monocytic surface antigens. The presence of 
TCRB gene rearrangement and absence of Ig heavy chain gene rear¬ 
rangement taken together with the marker studies provide con¬ 
clusive evidence that this patient had T-cell blast crisis. 
Furthermore, the presence of nongerm-line bcr fragments in crisis 
cells indicated that they were indeed part of the Ph'-positive 
clonal proliferation. 
While work on patient B.S. was in progress, Chan and Greaves 
et al [118] reported another case of T-cell blast crisis, also on 
the basis of a TCRB gene rearrangement and cell surface marker 
studies. These two cases are the only confirmed cases of T-cell 
blast crisis. Their significance is clear. First, they establish 
a new subset of patients with lymphoid blast crisis. Such pa¬ 
tients can now be examined for particular clinical features and 
response to therapy. Secondly, since CML arises from a bone 
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marrow stem cell, they confirm the bone marrow stem cell origin 
of T lymphocytes. Thirdly, they further confirm the pluripotent 
stem cell theory of CML. Now all hematopoietic cell lines, in¬ 
cluding T lymphocytes, have been shown to be involved in clonal 
CML proliferation. The difficulty in detecting Ph'-positive G6PD- 
monoclonal mature T lymphocytes in the peripheral blood during 
the chronic phase of CML has been circumvented by demonstrating 
the involvement of Ph'-positive T-lymphoid cells in blast crisis. 
The difficulty in detecting mature T lymphocyte involvement in 
the chronic phase has reasonably been attributed to the long 
survival of mature T lymphocytes. The rarity of T-lymphoid blast 
crisis can be explained similarly. Blast transformation occurs in 
Ph'-positive clonal cells. Assuming that this transformation is a 
random process, the frequency of its occurrence in a specific 
cell line should be determined by the relative rates of produc¬ 
tion of the various cell lines within the Ph'-positive clonal 
expansion. If it is also assumed that T cells have no growth 
advantage over other cell lines, the fact that they have a low 
rate of production accounts for the rarity of T-lymphoid blast 
crisis. Nevertheless, the presence in this study of one case of 
T-cell lymphoid blast crisis out of four lymphoid blast crisis 
cases suggests that it may not be as rare as previously thought. 
It is of course difficult to draw any statistically significant 
conclusions from such a small number of cases. 
The case of patient E.B. was less well defined. Originally 
thought to have ALL, she almost certainly had CML presenting in 
lymphoid blast crisis. Two points support this diagnosis. First, 
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during her remission post-chemotherapy, she had an abnormal peri¬ 
pheral blood picture typical of chronic phase CML with both 
elevated white blood cell count and a differential demonstrating 
myeloid forms of intermediate maturity. Secondly, bcr analysis in 
relapse DNA showed a breakpoint within that region. Whereas 
breakage within the bcr region is seen in virtually all cases of 
Ph'-positive CML, it has been noted in about half of patients 
diagnosed as having Ph'-positive ALL [26]. However, the idea has 
recently been advanced that the latter patients actually have CML 
and that they present with lymphoid blast crisis while patients 
with true Ph'-positive ALL have a breakpoint on chromosome 22 far 
upstream from the bcr region [119]. The diagnosis of lymphoid 
blast crisis was made in patient E.B. during her terminal relapse 
on the basis of blast cell morphology and TdT positivity. 
However, the only cell surface marker studies performed, with the 
antibodies Leu 4 and 14 (detecting pan-B and -T cell antigens, 
respectively), were negative. The finding of distinct rearrange¬ 
ments of both Ig heavy chain and TCRB genes clearly supported the 
diagnosis of lymphoid blast crisis. 
Two plausible hypotheses may be advanced to explain the dual 
rearrangement of Ig and TCRB genes. The first is that this 
patient may have had two lymphoid clones, one with a rearrange¬ 
ment of the Ig heavy chain genes, and hence of B-cell lineage, 
the other with rearrangement of TCRB genes, implying T-cell 
lineage. There is currently no way to test this hypothesis since 
leukemic cells were not sorted prior to DNA extraction and the 
patient is dead. There have, however, been no previous reports of 
mixed B-cell T-cell lymphoid blast crisis, and this is unlikely 
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to be the case here, especially since cell surface antigen 
studies were negative for both cell lines. 
The second, more plausible, explanation is that the patient 
had a lymphoid blast crisis involving an immature cell of either 
B- or T-cell lineage, or at a stage of maturation preceding the 
divergence of the two cell lines. This hypothesis is supported by 
the lack of B- and T-cell surface antigens. Dual rearrangements 
of Ig heavy chain and TCRB genes have been known to occur in 
immature blasts of some subtypes of ALL. In fact, 10% of patients 
with T-cell ALL (on the basis of cell surface antigens) and 30% 
of patients with non-B non-T cell ALL (on the basis of lack of B- 
and T-cell surface antigens and surface Ig) have cells with 
rearranged Ig heavy chain and TCRB genes [84,86,108,120]. Fur¬ 
thermore, the presence of such dual rearrangements has also been 
reported in more mature B lymphocytes, although with lower fre¬ 
quency than in immature cells. Specifically, 10% of B-cell CLL 
patients have rearranged TCRB genes in clonal lymphocytes 
[84,120]. 
Dual rearrangements of Ig and TCR genes have been found to be 
more frequent in leukemias of the precursor B-cell series. One of 
the more plausible explanations advanced for this observation is 
that rearrangement of both B- and T-cell genes within the same 
cell may be accomplished by use of the same molecular recom- 
binational mechanisms. Moreover, immature B cells are postulated 
to lack the signals present in mature cells that terminate gene 
rearrangement [107]. 
Regardless of the explanation, the presence of dual rear- 
' 
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rangements in the absence of cell surface antigens in crisis 
cells from patient E.B. suggests that the blast transformation 
occurred in an immature lymphoid cell. Although statistically it 
is more likely to be of B-cell lineage, the extent of TCRB gene 
rearrangement, resulting in complete deletion of C^^ argues 
for a T-cell lineage. It may even be artificial to speak of 
divergent B- and T-cell lines at this stage of cell maturation. 
The lineage of patient E.B.'s clonal lymphoid cells may be inves¬ 
tigated further by analysis of the arrangement of Ig light chain 
and TCRA genes. Mature B cells tend to have rearrangement of at 
least one light chain gene complex, and mature T cells tend to 
have rearrangement of the TCRA gene in addition to TCRG and TCRB 
genes [107]. Based on the apparent immaturity of this clone, 
however, it is likely that results of such studies would be 
negative. 
Two patients, M.P. and A.K., with lymphoid blast crisis 
demonstrated no detectable rearrangement of either Ig or TCRB 
genes. This finding is somewhat surprising since all lymphoid 
cells, unless quite immature, should be committed to either B- or 
T-cell lines and have started the gene rearrangement process 
[72]. Other than cell immaturity, the only explanation for fail¬ 
ure to detect Ig or TCR gene rearrangements is that the transfor¬ 
mations in these patients occurred in more mature B-cell pre¬ 
cursors (with Ig heavy chain gene rearrangement but not TCRB gene 
rearrangement) and that a relatively slight alteration in the 
size of the large Bam HI fragment used to detect Ig heavy chain 
rearrangement couldn't be detected. Obviously the next step for 
further characterization of the blasts in these two patients is 
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analysis for rearrangement of the kappa and lambda light chain 
genes. 
It is of interest that both lymphoid blast crisis patients 
with rearrangement of the TCRB genes had particulary aggressive 
disease with short time to development of crisis and short 
survival (patient B.S. with crisis at 5 months and death at 9 1/2 
months post-diagnosis; patient E.B. with presentation in crisis 
and death at 5 months post-diagnosis) whereas the two patients 
lacking rearrangement of these genes had more prolonged courses 
(patient A.K. transplanted prior to crisis with death in crisis 4 
years post-diagnosis; patient M.P. with crisis and death 9 years 
post-diagnosis). Although these four patients do not allow for 
statistically significant conclusions, this observation is still 
intriguing. It raises the question of whether patients who 
develop lymphoid blast crisis with rearranged TCRB genes undergo 
blastic transformation earlier than patients without this gene 
rearrangement. It is unfortunate that additional blast crisis 
patients with TCR gene rearrangements are not yet available for 
analysis. However, review of the few reported cases of possible 
T-cell lymphoid blast crisis based on surface markers alone does 
not support this hypothesis [20,73-77]. In fact, it may be more 
likely that a T-lymphoblastic transformation would occur in a 
patient who had remained in chronic phase for a relatively long 
period of time, a period adequate to allow for penetration of the 
Ph'-positive clone into the T-cell compartment and thus provide a 
substrate for T-lymphoblastic transformation. Further investiga¬ 
tion of blast crisis patients with and without TCR gene rear- 
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rangements is necessary to address these speculations. 
It is well established that chromosomal translocations in 
certain lymphoid malignancies bring proto-oncogenic genes under 
control of Ig heavy or light chain promoters. For example, in 
Burkitt's lymphoma with 8;14, 2;8, and 8;22 translocations, the 
c-myc gene on chromosome 22 comes under control of an Ig gene 
promoter, while in follicular lymphomas with a 14;18 transloca¬ 
tion, the bcl-1 gene comes under control of the Ig heavy chain 
promoter. These events are thought to play an important role in 
the genesis of these malignancies. It has been speculated that 
similar events may occur in T-cell malignancies whereby proto¬ 
oncogenes may come under control of TCR gene promoters. There¬ 
fore, leukemic blast cell DNA from patients B.S. and E.B. was 
examined by Southern analysis for rearrangement of the c-myc gene 
by Dr. C.M.I. Ahmed in the laboratory of Dr. P. Lebowitz. Rear¬ 
rangement was not detected, suggesting that in these two patients 
a translocation of the c-myc gene into either a TCR or Ig gene 
locus had not occurred. 
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